Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry.
Summary of "Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry."
Background: In survival analyses using cancer registry data, second and subsequent primary cancers diagnosed in individuals are typically excluded. However, this approach may lead to biased comparisons of survival between cancer registries, or over time within a single registry. Purpose: To examine the impact of including multiple primary cancers in the derivation of survival estimates using data from a population-based national cancer registry. Methods: Five-year relative survival estimates for persons aged 15-99 years at diagnosis were derived using all eligible primary cases from the Canadian Cancer Registry (CCR)-a population-based registry containing information on cases diagnosed from 1992 onward-and then again using first primary cases only. Any pre-1992 cancer history of persons on the CCR was obtained by using auxiliary information. Results: The inclusion of multiple cancers resulted in lower estimates of 5-year relative survival for virtually all cancers studied. The effect was somewhat attenuated by age-standardization (e.g., from 1.3% to 1.0% for all cancers combined), and was greatest for bladder cancer (-2.4%) followed by oral cancer (-1.9%)-cancers that had the first and third lowest proportions of first cancers, respectively. For the majority of cancers the difference was less than 1.0%. Cancers for which there was virtually no difference (e.g., lung, pancreatic, ovarian and liver) tended to be those with a poor prognosis. Conclusion: Inclusion of second and subsequent primary cancers in the analysis tended to lower estimates of relative survival, the extent of which varied by cancer and age and depended in part on the proportion of first primary cancers.
Health Statistics Division, Statistics Canada, Room 2200 Main Building, Section P, 150 Tunney's Pasture Driveway, Ottawa, ON, Canada K1A 0T6.
This article was published in the following journal.
Name: Cancer epidemiology
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20638928
- DOI: http://dx.doi.org/10.1016/j.canep.2010.06.015
Medical and Biotech [MESH] Definitions
Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
PURPOSE: Different rules for registering multiple primary (MP) cancers are used by cancer registries throughout the world, making international data comparisons difficult. This study evaluates the eff...
BACKGROUND: Little is known about the unique experience of adults with a history of multiple cancer diagnoses (i.e., survivors of multiple cancers). PURPOSE: This research assessed the health status a...
Abstract Background. Therapy for head and neck cancers has evolved over the past decade, but few detailed analyses of recent developments in survival on the population level have been published. Metho...
Objective: The presence of synchronous multiple primary non-small-cell lung cancers (SMPLC) is a rare condition and the optimal treatment remains unclear. In this study, the survival of surgically tre...
INTRODUCTION: Cytokines play a critical role in regulating the immune system. In the tumor microenvironment, they influence survival, proliferation, differentiation, and movement...
For the purposes of this study, as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; gluco...
The purpose of this research study is to determine if AZD6244 is safe and effective in treating patients with cancers with a mutated BRAF gene. AZD6244 is an investigational drug that work...
The investigators aim to explore the efficacy of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators investigate response, survival a...
The purpose of the PACE-MI registry is: - Analyze beta-blocker dose response effect on outcome over two years - Explore gender and minority differences in beta-blocker utilization...
The purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. This will be done by measuring the effect of tr...